AVIR insider trading
NasdaqGS HealthcareAtea Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Company website: ateapharma.com
AVIR insider activity at a glance
FilingIQ has scored 116 insider transactions for AVIR since Jul 27, 2016. The most recent filing in our index is dated Mar 11, 2026.
Across the full history, 9 open-market purchases
and 14 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AVIR insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AVIR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AVIR?
- FilingIQ tracks 116 Form 4 insider transactions for AVIR (Atea Pharmaceuticals, Inc.), covering filings from Jul 27, 2016 onwards. 2 of those were filed in the last 90 days.
- Are AVIR insiders net buyers or net sellers?
- Across the full Form 4 history for AVIR, 9 transactions (8%) were open-market purchases and 14 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AVIR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is AVIR in?
- Atea Pharmaceuticals, Inc. (AVIR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $368.37M.
Methodology & sources
Every AVIR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.